Discussion
Enrollment of adults with mild-to-moderate amyotrophic lateral sclerosis (ALS) has been completed in a clinical trial testing PHENOGENE-1A as an add-on treatment for the neurodegenerative disease. Enrollment of about 105 participants in the Phase 2b trial (NCT07142291) wrapped up in late August, and they were randomly assigned to…